BLFS (BioLife Solutions) Total Stockholders Equity: $372.23 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BLFS BioLife Solutions Inc BLFS
72 GF Score
Price $29.35
GF Value $28.83
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is BioLife Solutions Total Stockholders Equity?

BioLife Solutions BLFS +2.48% 72 Total Stockholders Equity is $372.23 Mil as of Mar. 2026. GuruFocus rates BLFS with a GF Score™ of 72/100 and a GF Value™ of $28.83 (Fairly Valued). The stock has 5 warning signs investors should review.

BioLife Solutions's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $372.23 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. BioLife Solutions's Book Value per Share for the quarter that ended in Mar. 2026 was $7.62. The ratio of a company's debt over equity can be used to measure how leveraged this company is. BioLife Solutions's Debt-to-Equity for the quarter that ended in Mar. 2026 was 0.04.

BioLife Solutions  (NAS:BLFS) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

BioLife Solutions's Book Value per Share for the quarter that ended in Mar. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(372.23-0)/48.825
=7.62

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

BioLife Solutions's Debt-to-Equity for the quarter that ended in Mar. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(4.815 + 10.042) / 372.23
=0.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioLife Solutions Total Stockholders Equity Related Terms

BioLife Solutions Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for BioLife Solutions's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioLife Solutions Total Stockholders Equity Chart

BioLife Solutions Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 478.05 364.19 337.66 348.91 371.89

BioLife Solutions Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 352.62 347.16 353.74 371.89 372.23
BLFS
72GF Score
BioLife Solutions Inc BLFS
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of $372.23 Mil mean?
BioLife Solutions (BLFS) has a Total Stockholders Equity of $372.23 Mil as of Mar. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for BioLife Solutions and its competitors.
Is BioLife Solutions' Total Stockholders Equity too high?
BioLife Solutions' current Total Stockholders Equity is $372.23 Mil. Overall, BioLife Solutions has a GF Score™ of 72/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BioLife Solutions' Total Stockholders Equity compare to STAA and ATRC?
BioLife Solutions' Total Stockholders Equity of $372.23 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Medical Devices & Instruments company?
A good Total Stockholders Equity depends on the Medical Devices & Instruments industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for BioLife Solutions and its competitors. BioLife Solutions's current Total Stockholders Equity is $372.23 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioLife Solutions stock overvalued right now?
Based on GuruFocus' analysis, BioLife Solutions (BLFS) is currently considered Fairly Valued. The stock's GF Value™ is $28.83, compared to a current price of $29.35 — trading 1.8% above its estimated fair value. The current Total Stockholders Equity is $372.23 Mil. BioLife Solutions' overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For BioLife Solutions (BLFS), the current Total Stockholders Equity is $372.23 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioLife Solutions (BLFS) Overvalued in 2026?

Based on GuruFocus' analysis, BioLife Solutions stock appears to be overvalued. The current stock price of $29.35 is trading 1.8% above its estimated GF Value™ of $28.83. GuruFocus considers BioLife Solutions to be Fairly Valued.

Key valuation signals for BLFS:

  • Total Stockholders Equity: $372.23 Mil
  • GF Value™: $28.83 vs. price of $29.35 (1.8% above fair value)
  • GF Score™: 72/100 with 5 warning signs

No single metric tells the full story. See the BLFS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioLife Solutions Business Description

Other Exchanges BJX1:Germany
Address 3303 Monte Villa Parkway, Suite 310, Bothell, WA, USA, 98021
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.
72GF Score

Get the complete analysis for BLFS

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$29.35
Price
$28.83
GF Value